Literature DB >> 23166921

Europe gives gene therapy the green light.

Karl Gruber.   

Abstract

Mesh：

Year:  2012        PMID： 23166921     DOI： 10.1016/s0140-6736(12)61992-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

2.  Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.

Authors:  Denis Horgan; Andres Metspalu; Marie-Christine Ouillade; Dimitrios Athanasiou; John Pasi; Oumeya Adjali; Patrick Harrison; Cedric Hermans; Giovanni Codacci-Pisanelli; Jasmina Koeva; Thomas Szucs; Viorica Cursaru; Ivica Belina; Chiara Bernini; Suijie Zhuang; Stephen McMahon; Draga Toncheva; Thomas Thum
Journal:  Biomed Hub       Date:  2020-12-03

3.  High capsid-genome correlation facilitates creation of AAV libraries for directed evolution.

Authors:  Mathieu Nonnenmacher; Harm van Bakel; Roger J Hajjar; Thomas Weber
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

Review 4.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

Review 5.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

Review 6.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

7.  Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).

Authors:  Shunji Tomatsu; Carlos J Alméciga-Díaz; Hector Barbosa; Adriana M Montaño; Luis A Barrera; Tsutomu Shimada; Eriko Yasuda; William G Mackenzie; Robert W Mason; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii
Journal:  Expert Opin Orphan Drugs       Date:  2013-10-01       Impact factor: 0.694

Review 8.  Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.

Authors:  Ryan D Geraets; Seung yon Koh; Michelle L Hastings; Tammy Kielian; David A Pearce; Jill M Weimer
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

9.  Gene therapies development: slow progress and promising prospect.

Authors:  Eve Hanna; Cécile Rémuzat; Pascal Auquier; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2017-01-03

10.  Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.

Authors:  Antoine H Chaanine; Mathieu Nonnenmacher; Erik Kohlbrenner; Dongzhu Jin; Jason C Kovacic; Fadi G Akar; Roger J Hajjar; Thomas Weber
Journal:  Gene Ther       Date:  2014-02-27       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.